Placental Growth Factor as a Predictor of Adverse Pregnancy Outcomes in Preeclamptic Women
Condition: Pre-Eclampsia
MeSH terms: Eclampsia; Pre-Eclampsia
Study type: Observational

Summary: 
      Background: Preeclampsia is one of the leading causes of maternal and perinatal morbidity and
      mortality worldwide, and it affects 3% to 8% of all pregnancies. Maternal and perinatal
      morbidity and mortality resulting from preeclampsia are due to its complications. Clinical
      prediction of complications associated with preeclampsia may facilitate initiation of timely
      management to reduce or avert adverse outcomes associated with the condition. Studies on
      current biomarkers (proteinuria or uric acid) have shown poor performance in the prediction
      of adverse pregnancy outcomes in preeclamptic women. Placental growth factor (PlGF) is an
      angiogenic growth factor that is exclusively produced by the trophoblast. Circulating levels
      of placental growth factor have been reported to be reduced in women with preeclampsia.
      Therefore there is a need to evaluate the predictive performance on adverse pregnancy
      outcomes of this pregnancy specific biomaker among preeclamptic women.

      Aim: To determine the predictive accuracy of maternal serum PlGF level for adverse pregnancy
      outcomes in preeclamptic women.

      Materials and Method: It is a prospective cohort study that will be conducted on 110 women
      that will be admitted for preeclampsia in the Federal Teaching Hospital and Saint Patrick
      Mile 4 Hospital Abakaliki. On admission women who will give informed consent will have their
      blood sample collected. The sample will be analysed using Enzyme linked Immunosorbent Assay
      technique to determine the level of PlGF (pg/ml). All the study participants will be followed
      up until delivery. The socio-demographic characteristics and maternal and perinatal adverse
      outcomes will be entered into a proforma. Data will be entered and analyzed using SPSS
      version 22.0.

      Strength and limitation: The strength of the study is that a single biomaker, PlGF, will be
      assayed and the test will be performed once, which is cost-saving. The limitation of this
      study is that there would not be long term follow up of participants after hospital discharge
      and so complications that will occur after discharge will not be assessed.

      Conclusion: Considering the contribution of preeclampsia to maternal morbidity and mortality
      in Abakaliki and poor predictive performance of available biochemical markers on adverse
      pregnancy outcomes among preeclamptic women, there is need to conduct this study so as to
      ascertain the utility of PlGF in predicting adverse outcome among preeclamptic women in
      Abakaliki.
    

Detailed description: 
      INTRODUCTION Despite advances in care, preeclampsia remains a leading cause of maternal and
      perinatal morbidity and mortality worldwide and its syndromic nature makes diagnosis and
      management difficult.1 Preeclampsia (PE) is a pregnancy-specific syndrome, defined by new
      onset hypertension and proteinuria after 20 weeks of gestation.2 It complicates 2-8% of
      pregnancies and accounts for more than 50,000 maternal death annually.2,3 In developing
      countries, where lack of access to appropriate maternal care is a major problem, maternal
      death rates are as high as 15% as compared with 0% to 1.8% in industrialized countries.1 A
      10-year review of maternal mortality in Ebonyi state University Teaching Hospital showed that
      PE and eclampsia accounted for 6.1% of maternal death.4 Preeclampsia affects multiple organ
      systems and can lead to severe maternal and fetal complications.5-10 Maternal and perinatal
      morbidity and mortality resulting from PE are due to its complications.6-8 Maternal
      complications include eclampsia, cerebrovascular accident, placental abruption, disseminated
      intravascular coagulation, hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome,
      liver hemorrhage or rupture, pulmonary edema, adult respiratory distress syndrome, acute
      renal failure, and death. Perinatal consequences include stillbirth, preterm delivery, fetal
      growth restriction (FGR), and neonatal death.5-10 The only curative treatment for PE is
      delivery of the placenta.9-13 The challenge in caring for women with PE is to identify those
      who are at increased risk of complications so that appropriate and timely delivery can be
      offered.14 Most of the symptoms associated with PE are common and nonspecific, which can lead
      to poor predictability of adverse outcomes.15 Moreover, the capacity to predict adverse
      maternal and perinatal outcomes remains poor.15 Recognition of those patients at risk of
      adverse outcomes related to PE can reduce or avert maternal and perinatal morbidity and
      mortality associated with the condition.16 Currently available biochemical makers such as
      proteinuria and uric acid have been shown to be poor predictors of adverse pregnancy outcomes
      in preeclamptic women.16-20 This suggests that a clinical diagnostic test able to predict
      maternal and fetal risk could be useful. Among biochemical markers, attention has recently
      focused on angiogenic factors, such as PlGF. Placental growth factor is an angiogenic growth
      factor related to vascular endothelial growth factor that is exclusively produced by the
      trophoblast.18 A growing body of evidence suggests that an imbalance of
      angiogenic/anti-angiogenic factors are involved in the pathophysiology of PE.18 Studies on
      the pathogenesis of PE support the hypothesis of a pathogenetic model of defective
      placentation resulting from reduced concentrations of angiogenic growth factors (free PlGF)
      and increased concentrations of anti-angiogenic factors such as soluble Fms-like tyrosine
      kinase-1 (sFlt-1).16-24 The majority of studies of PlGF testing have focused on either
      prediction of PE or confirmation of the diagnosis once PE is suspected. Even though this
      biomarker has excellent predictive value for PE, a major issue is that there is no clear
      intervention that can prevent the subsequent development of the disease. Several preventive
      measures such as supplementation with vitamin C and vitamin E, aspirin, or calcium fail to
      consistently prevent subsequent development of PE.19 Thus, the value remains either a
      "research procedure" or a method of risk assessment to identify patients who may benefit from
      more intensive surveillance. Currently studies are focused on evaluating the role of plasma
      angiogenic and anti-angiogenic factors in predicting the outcome of patients with PE. Studies
      have shown a positive correlation between low maternal serum PlGF levels and adverse maternal
      and fetal outcomes.21 These findings have led to speculation that PlGF might be useful in
      both the prediction of PE and prognosis with respect to the occurrence of related adverse
      outcomes.

      Considering the contribution of PE to maternal morbidity and mortality in Abakaliki and poor
      predictive accuracy of available biochemical markers on adverse pregnancy outcomes and the
      search for better predictive maker of adverse outcomes among preeclamptic women, a study on
      PlGF as a predictor of outcomes among preeclamptic women in Abakaliki is important.

      1.1 JUSTIFICATION FOR THE STUDY Preeclampsia has remained among the leading causes of
      maternal morbidity and mortality worldwide.22 Maternal deaths resulting from PE are due to
      complications associated with the condition.20-25 Clinical prediction of disease
      complications may facilitate initiation of timely management to prevent morbidity and
      mortality in the mother and baby. The studies on current predictive biomarkers (proteinuria
      or uric acid) of adverse outcomes among preeclamptic women have shown poor predictive
      results.24 Hence there is a need for identification of highly specific and sensitive
      biomarkers that would allow early identification of patients at risk and for prediction of
      adverse outcomes for women who developed the condition and thus help in providing proper
      prenatal care. Placental growth factor appears to be a promising tool in this regard.
      Literature search showed that this study has not been done in Abakaliki. Hence, the outcome
      of this study will help to make evidence based recommendations on the role of maternal serum
      level of PlGF in the management of preeclamptic women in Abakaliki.

      3.0 AIM AND OBJECTIVES AND RESEARCH QUESTION 3.1 AIM The aim of the study is to test the
      predictive accuracy of maternal free PlGF concentration for pregnancy adverse outcomes in
      patients with preeclampsia based on a single assay at the time of admission.

      3.2 SPECIFIC OBJECTIVES To compare the mean serum level of PlGF among preeclamptic women with
      and without adverse pregnancy outcomes.

      To evaluate the relationship between the level of PlGF and adverse maternal outcomes.

      To determine the association between serum PlGF level and adverse perinatal outcomes.

      To estimate the cut off value of PlGF associated with adverse pregnancy outcomes.

      To determine the sensitivity and specificity of cut off value of PlGF associated with adverse
      pregnancy outcomes.

      3.3 RESEARCH QUESTION Is maternal PlGF level predictive of adverse pregnancy outcomes in
      preeclamptic women in the Federal Teaching Hospital and Saint Patrick Mile 4 Hospital
      Abakaliki? 3.4 NULL HYPOTHESIS There is no association between maternal serum PlGF
      concentration and adverse pregnancy outcomes in preeclamptic women 3.5 ALTERNATE HYPOTHESIS
      There is an association between maternal PlGF level and adverse pregnancy outcomes in
      preeclamptic women.

      4.0 METHODOLOGY 4.1 STUDY AREA This study will be done at the antenatal ward, labour ward,
      postnatal ward and neonatal intensive care unit department of the Federal Teaching Hospital,
      Abakaliki, Ebonyi State.

      Federal Teaching Hospital, Abakaliki is a federal tertiary health care institution located at
      the state capital. It is a product of a merger of the former Federal Medical Centre,
      Abakaliki and the then Ebonyi State University Teaching Hospital by the Federal Government of
      Nigeria in 2011. The department of Obstetrics and Gynaecology of the hospital maintains
      gynaecological emergency, antenatal clinic, antenatal ward, labour ward, theatre complex and
      postnatal ward for both booked and unbooked patients. These are managed by Consultants and
      Resident Doctors with trained Nurses and Midwives. There are 25 Consultants manning 5 units
      in the department with an average of 5 Consultants per unit. The units run the antenatal and
      gynaecological clinics on each of the working days of the week. In 2017, three thousand and
      two hundred deliveries were taken and there were 204 cases of preeclampsia. The maternal
      mortality ratio in a 10 year review of maternal death in the hospital was 1, 359 per 100,000
      live births.4 Ebonyi State is one of the five states in the Southeast geopolitical zone of
      Nigeria created in 1996 from the old Abakaliki division of Enugu State and old Afikpo
      division of former Abia State. It has 13 local government areas with an estimated population
      of about 4.3 million, with a land mass of approximately 5, 932 sq km.33 The state is bordered
      in the north by Benue State, east by the Cross river Sate; south by Abia State and West by
      Enugu state.

      4.2 SAMPLING METHOD Total sampling method will be used for the study. All women diagnosed
      with preeclampsia on admission who meet the inclusion criteria and give informed consent will
      be recruited for the study. The study participants will be followed up until hospital
      discharge after delivery.

      4.3 DIAGNOSIS OF PREECLAMPSIA Measurement of blood pressure: Upper arm blood pressure will be
      measured by the researcher or research assistant using the Mercury Sphygmomanometer (ELKO B.P
      APPARATUS) after the study participant has rested for 5 minutes. All of the participants will
      be seated on a chair in an upright position with back support. A cuff will be placed around
      the non-dominant upper arm, which will be supported at the level of the heart; with the
      bladder of the cuff in the midline over the brachial artery pulsation. The systolic and
      diastolic blood pressures will be determined by Korokoff I and V respectively.

      Preeclampsia will be defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or
      diastolic blood pressure ≥ 90 mmHg on ≥ 2 recordings taken ≥ 4 hours apart after 20 weeks'
      gestation or a single measurement of systolic blood pressure of 160 mmHg and/or diastolic
      blood pressure of 110 mmHg with proteinuria (≥ 2+ by dipstick).

      4.4 SAMPLE SIZE ESTIMATION The sample size calculation was based on the formula N=Z^2 x
      SD^2/d^2 Z1-α = Standard normal variate at 5% type 1 error (P<0.05) is 1.96 SD = Standard
      deviation of variable based on previous studies (The SD of PlGF value which preeclamptic
      women were predicted to developed adverse pregnancy outcomes was 0.56. Note: 0.56 was derived
      by getting the average SD of PlGF for developing adverse pregnancy outcomes from two previous
      studies ).25,26 d = Absolute error or precision (set at 10%) Therefore, N= 120.5 Adding 10%
      attrition rate which is approximately 12. Therefore the sample size is 140.

      4.5 SPECIMEN COLLECTION AND TRANSPORT On admission women who give consent for the study will
      have their urine and blood samples taken. Bed side urinalysis to know the degree of
      proteinuria will be carried out by the researcher or research assistants using True-Screen
      Combi 11 reagent strips (Lifesane Biotech, USA). The blood sample will be taken and
      transferred to a universal specimen bottle and the specimen taken to the hospital laboratory
      for analysis.

      4.6 SPECIMEN PROCESSING, STORAGE AND ANALYSIS At laboratory processing of the specimen will
      be carried out by three medical laboratory scientists and the researcher. Assay will be
      performed as soon as 40 samples are ready. Estimation of free PlGF levels will be done by
      ELISA technique using the Human PlGF ELISA kit (Roche Diagnostics, Germany). The result of
      the test will be reported in pg/ml.

      4.7 QUALITY CONTROL Three medical laboratory scientists will be involved in the sample
      analysis with the aid of the researcher under the supervision of a chemical pathologist.
      Three laboratory scientists will be dedicated to sample analysis while the chemical
      pathologist will occasionally test random samples to ensure that the results are
      corresponding with results of the test samples from the other three.

      4.8 RESEARCH ASSISTANTS Research assistants comprise the 2 residents and 5 house officers
      from each team and each assigned a specific role to play during the study period. There will
      be three training sessions for the assistants during which the details of the study with the
      role of each assistant will be explained. Retraining sessions may be done in the course of
      the study if deemed necessary. Whatsapp chat group will be created for easy communication.

      4.9 DATA COLLECTION METHOD The data would be collected using a proforma that has four parts
      which include the socio-demographic characteristics of the study participants, Blood
      pressure, Urinalysis result, adverse maternal and perinatal outcomes and PlGF level. After
      delivery, data proforma sheets will be completed for all participants before entering the
      information into a database.

      4.10 STATISTICAL ANALYSIS The data analysis will be performed using the SPSS version 22.0
      program for Windows (IBM Corp. Amork, New York, U.S.A). Categorical variables would be
      presented as frequencies and percentages while continuous variables would be presented as
      mean ± standard deviation. The mean PlGF values of women with and without adverse outcomes
      will be compared using the Student's t-test. To determine the best cut off value of PlGF
      (designated as X) for the prediction of adverse outcomes, the receiver operating
      characteristic (ROC) curve analysis would be used and areas under the curve (AUC) calculated.
      Logistic regression would be used to determine the association between the cut off value of
      PlGF and each of the composite maternal and perinatal adverse outcomes. Multivariable
      logistic regression would be constructed to account for potentially confounding factors
      selected based on clinical information (maternal age, gestational age at presentation, parity
      and mode of delivery). The sensitivity and specificity would be determined for the cut point
      cited above. A p value <0.05 would be considered statistically significant.

      4.11.0 ETHICAL CONSIDERATION 4.11.1 ETHICAL APPROVAL Ethical approval for the study has been
      sought for and obtained from the hospital Research Ethics Committee with approval number
      FETHA/REC/VOL2/2018/041. Informed consent will be obtained from each study participants.

      4.12 SOURCE OF FUNDING There is no source of funding for this study. The researchers will
      bear the cost of the study.

      4.13 STRENGTH AND LIMITATION OF THE STUDY The strength of the study is that a single
      biomaker, PlGF, would be assayed and the test would be performed once, which is cost-saving.
      The limitation of this study is that long term follow up of participants will not be carried
      out and adverse outcomes that will occur following hospital discharge will not be assessed.
      In addition, reliable results are obtained when the assay procedure is performed with a
      complete adherence to good laboratory practice and this will be ensured by quality control
      that will be put in place in course of the study.
    

Intervention name(s): Placental growth factor
Intervention type(s): Diagnostic Test
Intervention description(s): On admission, the blood samples of consenting participants will be collected and analysed using enzyme linked immunosorbent assay technique to determine the level of PlGF (pg/ml).
Intervention MeSH terms: Mitogens
Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        The study participants will be drawn from pregnant women with late-onset preeclampsia
        attending antenatal care at the study facilities during the study period.
      
Keywords: Placental growth factor; Prediction; Adverse pregnancy outcomes; Pre-eclampsia